XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
Phase of Trial: Phase IV
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Omalizumab (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- Acronyms XTEND-CIU
- Sponsors Genentech
- 10 Aug 2017 Status changed from active, no longer recruiting to completed.
- 06 Mar 2017 Results analysing outcomes for the 24-week open-label period, presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 01 Jun 2016 Planned End Date changed from 1 Sep 2017 to 1 Mar 2017.